Valued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company dedicated to advancing ...

Shares of Pfizer Inc. PFE sank 0.52% to $26.72 Friday, on what proved to be an all-around rough trading session for the stock ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

Every investor in Pfizer Inc. ( NYSE:PFE) should be aware of the most powerful shareholder groups. We can see that ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.03% of ...

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.59 which represents a decrease of $-0.02 or -0.08% from the prior close of $26.61. The stock opened at $26.7 and touched a low of ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price fell 0.8% during trading on Thursday after UBS Group lowered their price target on the stock from $31.00 to $29.00. UBS Group currently has a ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Pfizer Inc. (NYSE:PFE – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings ...

(RTTNews) - Pfizer Inc. (PFE), on Friday, announced that its pivotal Phase 3 trial of investigational anti-PD-1 monoclonal antibody, Sasanlimab, in patients with BCG-naïve, high-risk non-muscle ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...